EDITOR'S DESK

  • 4 Takeaways From The World Biosimilar Congress
    4 Takeaways From The World Biosimilar Congress

    Throughout this whirlwind two-day event, the panelists addressed the challenges of patient education and uptake, the pharmacovigilance of biosimilars, and how to navigate varying regulatory requirements in the global market. But there were four key messages relayed throughout this conference that are worth noting.

Navigating Brazil’s Emerging Biosimilar Market

The Latin American markets, and especially Brazil, hold great promise for biosimilar development, PlantForm CEO Don Stewart says. In recent years, many partnerships have been launched in Brazil between local and international companies to bolster the country’s biosimilar development. However, there are a number of things companies looking to forge joint ventures in Brazil need to keep in mind for success.

Some Biopharma Haven’t Caught Outsourcing Enthusiasm

I often write – and you read – about those individuals at biopharma companies openly enthusiastic about outsourcing. Not too long ago, though, I ran into a person who seemed to outdo the others in absolute embrace of this model. But here’s the catch: Her company won’t allow her enthusiasm to be shared “on the record.”

“Growing” Biosimilars: How Plants Bolster Manufacturing Efficiency

Roughly 15 to 20 years ago, a number of pharmaceutical companies raised money to employ tobacco technology in drug development. Unfortunately, this rush did not lead to the success many were hoping for. However, the successes of recent players in this space suggest pharma could be entering a new age in plant-based manufacturing.

Will Medicare Part D Make Biosimilar Manufacturers Pay?

Despite biosimilars’ reputation as cheaper alternatives to costly biologics, Medicare Part D patients likely won’t see great savings at least not right away. According to a recent Avelare Health report, there are two ways patients could see reduced biosimilar out-of-pocket costs. But one of these solutions could place a big burden on biosimilar manufacturers. 

More From Editor's Desk

GUEST CONTRIBUTORS

More From Guest Contributors...

BIOPROCESSING WHITE PAPERS

Solid Dosage: Stacking Sacks Of Powder For Processing

By Robert G. McGregor, General Manager, Brookfield Engineering

Many powders and granular materials spend time in static storage prior to processing. They may be kept in bags, sacks, or special containers in a warehouse near the plant. Unfortunately, some powders will gain significant strength over time due to the pressure caused by the stacked sacks of material, leading to a product that will not discharge from the sacks when required.

Consistency In Raw Material Supply: Benefits Of Partnering With A Customer-Centric Supplier
Biopharmaceutical manufacturing processes today are critically dependent upon the ability of suppliers to provide consistent, on-time supply of quality raw materials. Therapeutic manufacturers are increasingly concerned about potential downtime associated with underperforming materials and are consequently looking for customer-centric suppliers who can help develop collaborative solutions that meet a variety of supply chain challenges. By SAFC Biosciences
More White Papers...

BIO INDUSTRY POSTERS

More Bioprocessing Posters...

ON-DEMAND WEBINARS

More Webinars On-Demand...